Compare SANA & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANA | CRMD |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.5M | 590.7M |
| IPO Year | 2021 | 2009 |
| Metric | SANA | CRMD |
|---|---|---|
| Price | $2.01 | $4.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $8.43 | ★ $15.60 |
| AVG Volume (30 Days) | ★ 2.6M | 1.9M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.24 | ★ 780.00 |
| EPS | N/A | ★ 0.57 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $8.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.49 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $2.00 | $4.82 |
| 52 Week High | $5.49 | $13.02 |
| Indicator | SANA | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 32.21 | 24.50 |
| Support Level | N/A | N/A |
| Resistance Level | $3.41 | $8.79 |
| Average True Range (ATR) | 0.19 | 0.52 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 15.96 | 1.24 |
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.